Asian patients. Unexplained, persistent proteinuria during routine urinalysis testing. Skeletal muscle effects (eg, myalgia, myopathy, & rhabdomyolysis, & potential immune-mediated necrotising myopathy); DM. Do not start treatment if creatinine kinase levels are significantly elevated at baseline (>10 x ULN). Predisposing factors for myopathy/rhabdomyolysis [eg, renal impairment, hypothyroidism, hereditary muscular disorders (personal or family history), history of muscular toxicity w/ other HMG-CoA reductase inhibitors, fibrate or niacin, alcohol abuse, elderly ≥65 yr, situations where increased plasma levels occur & concomitant use of fibrate or niacin]. Temporarily w/held in acute serious conditions suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (eg, sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine & electrolyte disorders or uncontrolled seizures). Increase incidence of myositis & myopathy in patients receiving other MHG-CoA reductase inhibitors together w/ gemfibrozil, cyclosporin, nicotinic acid, azole antifungals, PIs & macrolide antibiotics. Excessive alcohol consumption &/or history of liver disease. Moderate hepatic impairment. Dizziness may affect ability to drive or operate machinery. Use is limited to 1-yr period in childn & adolescents 10-17 yr.